Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
|Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific||Radiation: stereotactic radiosurgery||Phase 2|
|Study Design:||Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors|
|Study Start Date:||February 1999|
|Study Completion Date:||November 2004|
|Primary Completion Date:||November 2004 (Final data collection date for primary outcome measure)|
- Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.
- Assess the toxicities of this treatment regimen in these patients.
- Determine tumor response and cause of death in these patients treated with this regimen.
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006456
|United States, Virginia|
|Massey Cancer Center|
|Richmond, Virginia, United States, 23298-0058|
|Study Chair:||Danny Y. Song, MD||Massey Cancer Center|